The drug is already available in 35 countries

Sun Pharmaceutical Industries announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.

“ILUMYA offers a safe and effective treatment option for patients who are struggling to manage their moderate-to-severe plaque psoriasis,” said Kirti Ganorkar, Managing Director, Sun Pharma. “We are pleased to introduce this novel therapy in India from our global portfolio of innovative medicines. Already available in 35 countries, ILUMYA has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years.”

“Having been involved in the clinical development of Tildrakizumab in India, I am pleased to see its potential as an effective, safe, and long-lasting treatment for psoriasis. In the Phase-3 trial, tildrakizumab demonstrated significant improvements across all measures, with approximately 93.5% reduction in PASI score and pronounced skin clearance.” said Dr BS Chandrashekar, Chief Dermatologist and Managing Director, Cutis Academy of Cutaneous Sciences, Bengaluru, India who was also an investigator in India Phase 3 trial. “These results showcase its benefits in improving the quality of life for psoriasis patients.”